incretin mimetic agents glp 1 receptor agonists Incretins: How we got here, where we're at and what is coming next GLP-1 receptor agonists and next-generation

For patients interested in GLP-1 medications specifically for type 2 diabetes rather than weight management, the path is often simpler

8 Even if you can afford treatment, getting the drugs is another story

Over the past decades, researchers overcame significant challenges such as the hormones very short half-life in the body to develop long-acting GLP-1 receptor agonist drugs

Zhou B, Caudal A, Tang X, Chavez JD, McMillen TS, Keller A, et al

Finally, one can foresee a future where combination therapy becomes common: for example, a patient with diabetes and obesity might be on both a GLP-1 RA and an SGLT2 inhibitor (for complementary weight loss and cardio-renal protection, which is already done)

Our providers are ready to support you.